A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma

Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Cytologically or histologically confirmed diagnosis of hepatocellular carcinoma (HCC)

- Advanced or metastatic disease

- Not a candidate for curative treatments (that is, resection, transplantation)

- Child-Pugh class A liver function

- Measurable disease as defined by Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1

- Life expectancy greater than (>) 3 months

- For participants who received prior adjuvant chemotherapy, a treatment-free interval
of at least 6 months between the last chemotherapy cycle and Cycle 1 Day 1

Exclusion Criteria:

- Prior surgery or local therapy within 4 weeks prior to Cycle 1 Day 1, with the
exception of palliative radiation therapy to the bone

- Brain metastasis or spinal cord compression not definitively treated with surgery
and/or radiation

- Granulocyte count less than (<) 1500 per cubic millimeter (mm^3), platelet count <
75,000/mm^3, and hemoglobin < 8 gram per deciliter (g/dL) within 7 days prior to
Cycle 1 Day 1

- Total bilirubin greater than (>) 1.5 times the upper limit of normal (ULN)

- Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT),
Alanine transaminase (ALT) serum glutamic-pyruvic transaminase (SGPT), alkaline
phosphatase (ALP) > 5 × ULN

- Serum creatinine > 1.5 × ULN or creatinine clearance < 60 cubic centimeter per minute
(cc/min) by Cockcroft-Gault formula

- Significant history of cardiac disease within 6 months prior to Cycle 1 Day 1,
myocardial infarction within the previous year, or current cardiac ventricular
arrhythmias requiring medication

- Serious active infection, or other serious underlying medical conditions that would
impair the ability of the participant to receive protocol treatment, with the
exception of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections

- Known active infection with human immunodeficiency virus (HIV) or known
HIV-seropositivity

- Inability to take oral medication or untreated malabsorption syndrome

- Pregnant or lactating women

- History of transplantation including organ, bone marrow transplantation, and
peripheral blood stem cell transplantation with the exception of corneal
transplantation

- Active bleeding diathesis (including active esophageal varices) or tumor rupture
within 8 weeks prior to Cycle 1 Day1 that are not successfully treated

- Uncontrolled hypertension

- Treatment with any other investigational drug within 4 weeks of Cycle 1 Day